PharmaSGP Holding SE (PSG.DE)
EUR 24.8
(4.2%)
EUR 24.8
(4.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 91.54 Million EUR | -6.6% |
| 2022 | 98.01 Million EUR | 5.32% |
| 2021 | 93.06 Million EUR | 592.58% |
| 2020 | 13.43 Million EUR | 64.65% |
| 2019 | 8.16 Million EUR | 6.48% |
| 2018 | 7.66 Million EUR | -26.02% |
| 2017 | 10.36 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 101.54 Million EUR | 5.49% |
| 2024 Q1 | 96.26 Million EUR | 5.15% |
| 2023 Q4 | 91.54 Million EUR | -3.55% |
| 2023 Q1 | 100.18 Million EUR | 2.22% |
| 2023 Q2 | 100.92 Million EUR | 0.74% |
| 2023 FY | 91.54 Million EUR | -6.6% |
| 2023 Q3 | 94.91 Million EUR | -5.95% |
| 2022 Q3 | 97.94 Million EUR | -1.61% |
| 2022 Q1 | 95.46 Million EUR | 2.58% |
| 2022 FY | 98.01 Million EUR | 5.32% |
| 2022 Q4 | 98.01 Million EUR | 0.07% |
| 2022 Q2 | 99.54 Million EUR | 4.27% |
| 2021 Q2 | 12.32 Million EUR | -6.14% |
| 2021 FY | 93.06 Million EUR | 592.58% |
| 2021 Q4 | 93.06 Million EUR | -14.86% |
| 2021 Q3 | 109.3 Million EUR | 787.03% |
| 2021 Q1 | 13.12 Million EUR | -2.29% |
| 2020 Q1 | 9.91 Million EUR | 21.44% |
| 2020 FY | 13.43 Million EUR | 64.65% |
| 2020 Q4 | 13.43 Million EUR | 10.38% |
| 2020 Q3 | 12.17 Million EUR | -24.64% |
| 2020 Q2 | 16.15 Million EUR | 62.99% |
| 2019 FY | 8.16 Million EUR | 6.48% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 8.16 Million EUR | 0.0% |
| 2018 FY | 7.66 Million EUR | -26.02% |
| 2017 FY | 10.36 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| MPH Health Care AG | 15.38 Million EUR | -494.97% |
| Apontis Pharma AG | 27.2 Million EUR | -236.563% |
| Dermapharm Holding SE | 1.62 Billion EUR | 94.373% |
| Evotec SE | 1.17 Billion EUR | 92.236% |
| MERCK Kommanditgesellschaft auf Aktien | 22.36 Billion EUR | 99.591% |
| SynBiotic SE | 19.59 Million EUR | -367.282% |